Biochemistry

   

Simultaneous Estimation of Emtricitabine and Tenofovir Disoproxil Fumarate in Tablet Dosage Form by Reverse Phase High-performance Liquid Chromatography

Authors: Bala Rami Reddy.Yenumula, Mutta Reddy.Singampalli, Bala Sekhara Reddy.Challa

A simple, rapid reversed-phase high performance liquid chromatographic method had been developed and validated for estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form. The estimation was carried out on PhenomenexLuna C18 (25 cm x 4.60 mm, particle size 5 µm) column with a mixture of 10mM phosphate buffer (pH 6.8): Acetonitrile; 40: 60 (v/v) as mobile phase. UV detection was performed at 260 nm. The method was validated for linearity, accuracy, precision, specificity and sensitivity as per ICH norms. The developed and validated method was successfully used for the quantitative analysis of commercially available dosage form. The retention time was 2.81 and 7.42 min for emtricitabine and tenofovir disoproxil fumarate respectively and total run time was 10 min. at a flow rate of 1.0 mL/ min. The calibration curve was linear over the concentration range of 40.00 - 240.00 µg/ mL for emtricitabine and 60.00 - 360.00 µg/ mL for tenofovir disoproxil fumarate. The LOD and LOQ values were found to be 1.54 and 4.54 µg/ mL for emtricitabine and 4.60 and 13.65 µg/ mL for tenofovir disoproxil fumarate respectively. The high percentage of recovery and low percentage coefficient of variance confirm the suitability of the method for the simultaneous estimation of emtricitabine and tenofovir disoproxil fumarate in tablet dosage form. You can submit your Manuscripts at:  https://symbiosisonlinepublishing.com/submitManuscript.php 

Comments: 6 Pages.

Download: PDF

Submission history

[v1] 2017-08-28 02:26:25

Unique-IP document downloads: 11 times

Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.

Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.

comments powered by Disqus